T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Cited by (1,002)

Items 601–700 of 1,002

1. An exhausted phenotype of TH2 cells is primed by allergen exposure, but not reinforced by allergen‐specific immunotherapy
   Shu‐Hung Wang, Ulrich M. Zissler, Maren Büttner, Sonja Heine, Alexander Heldner, Sebastian Kotz, Lisa Pechtold, Josephine Kau, Mirjam Plaschke, Julia T. Ullmann et al. · 2021 · Allergy
2. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
   Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges et al. · 2022 · Journal for ImmunoTherapy of Cancer
3. Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy
   Xinlun Dai, Xin Li, Yahui Liu, Fei Yan · 2022 · Materials & Design
4. Computational design of PD-L1 small molecule inhibitors for cancer therapy
   Jaikanth Chandrasekaran, Senthilkumar Elumalai, Vidya Murugesan, Selvaraj Kunjiappan, Parasuraman Pavadai, Panneerselvam Theivendren · 2022 · Molecular Diversity
5. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes
   Lucas A. Horn, Tiha M. Long, Ryan S. Atkinson, Virginia K. Clements, Suzanne Ostrand‐Rosenberg · 2017 · Cancer Immunology Research
6. PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis
   Joseph A. Pereira, Zachary R. Lanzar, Joseph T. Clark, Andrew P. Hart, Bonnie B. Douglas, Lindsey A. Shallberg, Keenan M. O’Dea, David A. Christian, Christopher A. Hunter · 2023 · Frontiers in Immunology
7. PD-1 inhibits T cell actin remodeling at the immunological synapse independently of its signaling motifs
   Noémie Paillon, Violette Mouro, Stéphanie Dogniaux, Mathieu Maurin, Juan José Sáez, Hermine Ferran, Laurence Bataille, Andres Ernesto Zucchetti, Claire Hivroz · 2023 · Science Signaling
8. TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments
   Yuan-Li Tsai, Marcel Arias-Badia, Theresa A. Kadlecek, Yee May Lwin, Aahir Srinath, Neel H. Shah, Zhi‐En Wang, Diane L. Barber, John Kuriyan, Lawrence H. Fong et al. · 2023 · Immunity
9. Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?
   Xun Chen, Steffen Johannes Keller, Philipp Hafner, Asma Y. Alrawashdeh, Thomas Yul Avery, Johana Norona, Jinxue Zhou, Dietrich Alexander Ruess · 2024 · Frontiers in Immunology
10. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives
    Manman Lu, Yu Yang · 2024 · Frontiers in Immunology
11. Protein post-translational modifications and tumor immunity: A pan-cancer perspective
    Haoling Zhang, Qilu Yan, Shuya Jiang, Dan Hu, Ping Lu, Shaowei Li, Doblin Anak Sandai, Haolong Zhang, Wangzheqi Zhang, Chenglong Zhu · 2025 · Physics of Life Reviews
12. Lipopolysaccharide suppresses T cells by generating extracellular ATP that impairs their mitochondrial function via P2Y11 receptors
    Koichiro Sueyoshi, Carola Ledderose, Yong Shen, Albert H. Lee, Nathan Ivan Shapiro, Wolfgang Georg JUNGER · 2019 · Journal of Biological Chemistry
13. Biophysical basis underlying dynamic Lck activation visualized by ZapLck FRET biosensor
    Rongxue Wan, Jenny Wu, Mingxing Ouyang, Lei Lei, Jiaming Wei, Qin Peng, Reed E. S. Harrison, Yiqian Wu, Binbin Cheng, Kaitao Li et al. · 2019 · Science Advances
14. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
    Diederick J. van Doorn, Robert Bart Takkenberg, Heinz‐Josef Klümpen · 2020 · Pharmaceuticals
15. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
    Cheng Frank Zhong, Yirun Li, Jing Yang, Shengxi Jin, Guoqiao Chen, Duguang Li, Xiaoxiao Fan, Hui Min Lin · 2021 · Frontiers in Oncology
16. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases
    Jorge Ibañez-Vega, Constanza Vilchez, Karin Jimenez, Carlos Guevara O, Paula Isabel Burgos, Rodrigo Fernandes Naves · 2021 · Journal of Autoimmunity
17. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer
    Hao Chen, Tao Jiang, Fang-Yu Lin, Hongdan Guan, Jianwei Zheng, Qing Liu, Bing Du, Yeyuan Huang, Xiaoyan Lin · 2021 · International Immunopharmacology
18. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
    Trevor S. Anderson, Amanda L. McCormick, Savanna L Piersall, Izuchukwu F. Okpalanwaka, Devin B. Lowe · 2022 · Seminars in Cancer Biology
19. Combination Approaches to Target PD-1 Signaling in Cancer
    Emily K. Moore, Marianne Strazza, Adam Mor · 2022 · Frontiers in Immunology
20. Employing Piezoelectric Mg 2+ ‐Doped Hydroxyapatite to Target Death Receptor‐Mediated Necroptosis: A Strategy for Amplifying Immune Activation
    Jiani Yang, Yaqian Du, Yuanfei Yao, Yuanyu Liao, Bojun Wang, Xuefan Yu, Kaikun Yuan, Yanqiao Zhang, Fei He, Piaoping Yang · 2024 · Advanced Science
21. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer
    Yan Wang, Yanhong Chen, Ding‐Kun Ji, Yuelin Huang, Weixi Huang, Xue Dong, Defan Yao, Dengbin Wang · 2024 · Journal of Nanobiotechnology
22. Checkpoint therapy in cancer treatment: progress, challenges, and future directions
    Mesude Bicak, Cansu Cimen Bozkus, Nina Bhardwaj · 2024 · Journal of Clinical Investigation
23. Lymph nodes fuel KLF2-dependent effector CD8+ T cell differentiation during chronic infection and checkpoint blockade
    Carlson Tsui, Leonie Heyden, Lifen Wen, Catarina Gago de Graça, Nikita Potemkin, Aleksej Frolov, Daniel Rawlinson, Lei Qin, Verena C. Wimmer, Marjan Hadian-Jazi et al. · 2025 · Nature Immunology
24. Advances in engineering immune–tumor microenvironments on-a-chip: integrative microfluidic platforms for immunotherapy and drug discovery
    Farnaz Dabbagh Moghaddam, Ali Anvar, Ehsan Ilkhani, Delara Dadgar, Maedeh Rafiee, Najmeh Ranjbaran, Pejman Mortazavi, Seyed Majid Ghoreishian, Yun Suk Huh, Pooyan Makvandi · 2025 · Molecular Cancer
25. PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension
    Lai Jiang, Chaoliang Tang, Yanping Gong, Yujie Liu, Jie Rao, Suyu Chen, Wanjun Qu, Dabao Wu, Lei Lei, Ling Chen · 2018 · Brazilian Journal of Medical and Biological Research
26. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma
    Maolang Tian, Jianping Yang, Jiaqi Han, Jinlan He, Wenjun Liao · 2020 · International Immunopharmacology
27. Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints
    Martina Kreileder, Ian P. Barrett, Claus Bendtsen, Donal J. Brennan, Walter Kölch · 2020 · Trends in Cell Biology
28. Point‐of‐critical‐care diagnostics for sepsis enabled by multiplexed micro and nano sensing technologies
    Brandon K. Ashley, Umer Hassan · 2021 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
29. Research progress of tumor targeted drug delivery based on PD-1/PD-L1
    Dongzhu Liu, Shan Gao, Yujia Zhai, Xiaoye Yang, Guangxi Zhai · 2022 · International Journal of Pharmaceutics
30. The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
    Anna Pawłowska, Wiktoria Skiba, Dorota Suszczyk, Weronika Kuryło, Joanna Jakubowicz-Gil, Roman Paduch, Iwona Wertel · 2022 · Cancers
31. Macrophage–Neuroglia Interactions in Promoting Neuronal Regeneration in Zebrafish
    Chih‐Wei Zeng · 2023 · International Journal of Molecular Sciences
32. Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway
    Ciputra Adijaya Hartana, Emma Ahlén Bergman, A. Ali Zirakzadeh, David Krantz, Malin Elisabeth Winerdal, Max Winerdal, Markus Johansson, Farhood Iranparvar Alamdari, Tomasz Jakubczyk, Hans Glise et al. · 2018 · PLoS ONE
33. PD‐L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment
    Takehara, Tomohiro, Wakamatsu, Ei, Machiyama, Hiroaki, Nishi, Wataru, Emoto, Katsura, Azuma, Miyuki, Soejima, Kenzo, Fukunaga, Koichi, Yokosuka, Tadashi · 2021 · Communications Biology
34. Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes
    Ornella Franzese · 2024 · International Journal of Molecular Sciences
35. Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
    Magdalena K. Zielińska, Magdalena A. Ciążyńska, Dorota Sulejczak, Piotr Lukasz Rutkowski, Anna Malgorzata Czarnecka · 2025 · Biomolecules
36. Association of combined PD ‐L1 expression and tumour‐infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma
    Coraline Bence, Véronique Hofman, Emmanuel Chamorey, Élodie Long-Mira, Sandra Lassalle, Anne Flore Albertini, Ioannis Liolios, Katia Zahaf, Alexandra Picard, Henri Montaudié et al. · 2019 · Journal of the European Academy of Dermatology and Venereology
37. Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust in vivo anti‐tumour efficacy
    Chenglong Liu, Feilong Zhou, Ziqin Yan, Lian Shen, Xichen Zhang, Fenglian He, Heng Wang, Xiaojie Lu, Ker Yu, Yujun Zhao et al. · 2021 · British Journal of Pharmacology
38. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma
    Rossella Puglisi, Maria Bellenghi, Giada Pontecorvi, Giulia Pallante, Alessandra Carè, Gianfranco Mattia · 2021 · Cancers
39. Inhibition of SHP2 as an approach to block RAS-driven cancers
    Yu‐Ting Chou, Trever Grant Bivona · 2022 · Advances in cancer research
40. Progress of small molecules for targeted protein degradation: PROTACs and other technologies
    Hongyi Zhao, Minhang Xin, San‐Qi Zhang · 2023 · Drug Development Research
41. Menstrual blood-derived mesenchymal stromal cells: impact of preconditioning on the cargo of extracellular vesicles as potential therapeutics
    María Ángeles de Pedro, Esther López, Francisco Manuel González-Nuño, María Pulido, Verónica Álvarez, Ana María Marchena, Christian Preußer, Witold G. Szymanski, Elke Pogge von Strandmann, Johannes Graumann et al. · 2023 · Stem Cell Research & Therapy
42. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer
    Matteo Bellone, Angela Rita Elia · 2017 · Cytokine & Growth Factor Reviews
43. Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
    Grace Mallett, Arian D. J. Laurence, Shoba Amarnath · 2019 · International Journal of Molecular Sciences
44. Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
    Peter S. Linsley, Sarah Alice Long · 2019 · Current Opinion in Endocrinology Diabetes and Obesity
45. Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice
    Moreno-Lama, Lucia, Galindo-Campos, Miguel A., Martínez, Carlos, Comerma, Laura, Vazquez, Ivonne, Vernet-Tomas, María, Ampurdanés, Coral, Lutfi, Nura, Martin-Caballero, Juan, Dantzer, Françoise et al. · 2020 · Oncogene
46. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
    Deng, Mi, Chen, Heyu, Liu, Xiaoye, Huang, Ryan, He, Yubo, Yoo, Byounggyu, Xie, Jingjing, John, Samuel, Zhang, Ningyan, An, Zhiqiang et al. · 2021 · Antibody Therapeutics
47. Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
    Tetsuichi Kansha, Shuai Ma, Hao Wang, Xiaotong Yu, Ying Song, Zhengyang Guo, Jiagui Song, Lixiang Xue, Jianling Yang · 2025 · Frontiers in Immunology
48. Hsa-miR-99b/let-7e/miR-125a Cluster Regulates Pathogen Recognition Receptor-Stimulated Suppressive Antigen-Presenting Cells
    Dagmar Hildebrand, Mariel-Esther Eberle, Sabine J. Wölfle, Franziska Egler, Delal Sahin, Aline Sähr, Konrad A. Bode, Klaus M. Heeg · 2018 · Frontiers in Immunology
49. Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries
    Mohamed S. Abdel-Hakeem · 2019 · Viruses
50. Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
    Thomas J. Gardner, Christopher M. Bourne, Megan M. Dacek, Keifer G. Kurtz, Manish Malviya, Leila Peraro, Pedro C. Silberman, Kristen C. Vogt, Mildred J. Unti, Renier J. Brentjens et al. · 2020 · Cancers
51. Using CRISPR to enhance T cell effector function for therapeutic applications
    Julian J. Freen‐van Heeren · 2020 · Cytokine X
52. Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients
    Fei Mao, Chao Yang, Weiyu Luo, Yijin Wang, Jie Xie, Hengbing Wang · 2022 · International Immunopharmacology
53. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
    Longchao Liu, Jiahui Chen · 2022 · Medical Review
54. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer
    Yu Xin, Chenguang Liu, Dan Zang, Jun Chen · 2024 · Frontiers in Immunology
55. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma
    Jean‐Marie Michot, Julien Lazarovici, David Ghez, Alina Danu, Christophe Fermé, Amélie Bigorgne, Vincent Ribrag, Aurélien Marabelle, Sandrine Aspeslagh · 2017 · European Journal of Cancer
56. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
    David Carbone, Michael F. Sharpnack, Kai He, Lisa Helene Butterfield, Alexander M.M. Eggermont, María González‐Cao, Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowskyj et al. · 2018 · Journal of Translational Medicine
57. Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
    Alireza Tojjari, Anwaar Saeed, Arezoo Sadeghipour, Razelle Kurzrock, Ludimila L. Cavalcante · 2023 · Cancers
58. Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II
    Ei Wakamatsu, Hiroaki Machiyama, Hiroko Toyota, Arata Takeuchi, Ryuji Hashimoto, Haruo Kozono, Tadashi Yokosuka · 2024 · Cell Reports
59. PD-1 and CTLA-4: Two checkpoints, one pathway?
    Lucy S. K. Walker · 2017 · Science Immunology
60. Development, ontogeny, and maintenance of TCRαβ+ CD8αα IEL
    Roland Ruscher, Kristin Ann Hogquist · 2019 · Current Opinion in Immunology
61. Tumor hypermetabolism confers resistance to immunotherapy
    Arthur J. Liu, Michael A. Curran · 2020 · Seminars in Cancer Biology
62. Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
    Mario Sznol, Ignacio Melero · 2020 · Annals of Oncology
63. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation
    Massimiliano Anselmi, Jochen S. Hub · 2021 · Proceedings of the National Academy of Sciences
64. Strategies for developing PD-1 inhibitors and future directions
    Wensheng Chen, Yuan Huang, Wenting Pan, Meng Xu, Liang Chen · 2022 · Biochemical Pharmacology
65. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
    Akira Ooki, Hiroki Osumi, Keisho Chìn, Masayuki Watanabe, Kensei Yamaguchi · 2023 · Therapeutic Advances in Medical Oncology
66. Fine tuning subsets of CD4+ T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases
    Zhen Zhao, Xiaojuan Zhang, Lili Su, Le Xu, Yong Zheng, Jian M. Sun · 2018 · International Immunopharmacology
67. Integrative network modeling reveals mechanisms underlying T cell exhaustion
    Hamid Bolouri, Mary H. Young, Joshua N. Beilke, Rebecca Johnson, Brian A. Fox, Lu Huang, Cristina Costa Santini, Christopher Mark Hill, Anne-Renée Van der Vuurst de Vries, Paul T. Shannon et al. · 2020 · Scientific Reports
68. Lattice Light-Sheet Microscopy Multi-dimensional Analyses (LaMDA) of T-Cell Receptor Dynamics Predict T-Cell Signaling States
    Jillian N. Rosenberg, Guoshuai Cao, Fernanda Borja-Prieto, Jun Huang · 2020 · Cell Systems
69. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer
    Guoliang Wang, Lejian He, Shengcai Wang, Meng Zhang, Yanzhen Li, Qiaoyin Liu, Nian Sun, Xuexi Zhang, Yuwei Liu, Jie Zhang et al. · 2020 · The Journal of Clinical Endocrinology & Metabolism
70. Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma
    Leyre Silva, Josune Egea, Lorea Villanueva, Marta Ruiz, Diana Llópiz, David Repáraz, Belén Aparicio, Aritz Lasarte-Cía, Juan José Lasarte, Marina Ruiz de Galarreta et al. · 2020 · Cancers
71. PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity
    Helen Parry, Alexander C. Dowell, Jianmin Zuo, Kriti Verma, Francesca A. M. Kinsella, Jusnara Begum, Wayne D. Croft, Archana Sharma‐Oates, Guy Pratt, Paul A. H. Moss · 2021 · PLoS Pathogens
72. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program
    Javier Arranz‐Nicolás, Miguel Martin-Salgado, Irene Adán‐Barrientos, Rosa Liébana, María del Carmen Moreno-Ortíz, Judith Maria Leitner, Peter Steinberger, Antonia Ávila‐Flores, Isabel Mérida · 2021 · Cancer Immunology Immunotherapy
73. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer
    Xiaoyu Chen, Chengxia Shu, Wenqiang Li, Qiangqiang Hou, Guangmei Luo, Kexin Yang, Xiaoxing Wu · 2022 · Journal of Medicinal Chemistry
74. Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
    Danielle Rosa Beserra, Ricardo Wesley Alberca, Anna Cláudia Calvielli Castelo Branco, Luana de Mendonça Oliveira, Milena Mary de Souza Andrade, Sarah Cristina Gozzi-Silva, Franciane Mouradian Emidio Teixeira, Tatiana Mina Yendo, Alberto José da Silva Duarte, Maria Notomi Sato · 2022 · Journal of Immunology Research
75. PROTACs in gastrointestinal cancers
    Yu Chen, Qingfan Yang, Jinrun Xu, Liyao Tang, Yan Zhang, Fukuan Du, Yueshui Zhao, Xu Wu, Mingxing Li, Jing Shen et al. · 2022 · Molecular Therapy — Oncolytics
76. TLR4 signaling improves PD-1 blockade therapy during chronic viral infection
    Yidan Wang, Young Rock Chung, Simon Eitzinger, Nicole M. Palacio, Shana Gregory, Mitra Bhattacharyya, Pablo Penaloza‐MacMaster · 2019 · PLoS Pathogens
77. Stem-like CD8+ T cells in cancer
    Chelsea Steiner, Nathan Denlinger, Xiaopei Huang, Yiping Yang · 2024 · Frontiers in Immunology
78. Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma
    Chen Liu, Xiaolong Miao, Yao Wang, Liang Wen, Xiawei Cheng, Deqiang Kong, Pengwei Zhao, Dandan Song, Xinyi Wang, Xianfeng Ding et al. · 2020 · Cancer Science
79. Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
    Gaopeng Li, Guoliang Wang, Fenqing Chi, Yuqi Jia, Xi Wang, Quankai Mu, Keru Qin, Xiaoxia Zhu, Jing Pang, Baixue Xu et al. · 2021 · Journal for ImmunoTherapy of Cancer
80. SILAC Phosphoproteomics Reveals Unique Signaling Circuits in CAR-T Cells and the Inhibition of B Cell-Activating Phosphorylation in Target Cells
    Alijah A. Griffith, Kenneth P. Callahan, Nathan Gordo King, Qian Xiao, Xiaolei Su, Arthur R. Salomon · 2022 · Journal of Proteome Research
81. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
    Tao Wang, Desirée Denman, Silvia M. Bacot, Gerald M. Feldman · 2022 · Biomedicines
82. Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
    Ruixuan Geng, Hui Jun Tang, Tingting You, Xiuxiu Xu, Sijian Li, Zepeng Li, Yuan Liu, Wei Qiu, Na Zhou, Ningning Li et al. · 2023 · Frontiers in Immunology
83. Neoepitopes-based vaccines: challenges and perspectives
    Vincent Alcazer, Paola Bonaventura, Laurie Tonon, Sandrine Valsesia‐Wittmann, Christophe Caux, Stéphane Depil · 2019 · European Journal of Cancer
84. XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections
    Eva Domenjo‐Vila, Valentina Casella, Ryutaro Iwabuchi, Even Fossum, Mireia Pedragosa, Quim Castellví, Paula Cebollada Rica, Tsuneyasu Kaisho, Kazutaka Terahara, Gennady Alekseevich Bocharov et al. · 2023 · Cell Reports
85. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors
    Xin‐Yu Chen, Bin Li, Ye Wang, Juan Jin, Yu Zhong Yang, Leihuan Huang, Meng‐Di Yang, Jian Zhang, Biyun Wang, Zhi‐Ming Shao et al. · 2023 · 癌症：英文版
86. Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy
    Simin Xiang, Sen Li, Junfen Xu · 2025 · Clinical and Translational Medicine
87. Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells
    Janna Krueger, Christopher E. Rudd · 2017 · Immunity
88. Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion
    Mumtaz Yaseen Balkhi · 2020 · OncoImmunology
89. The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?
    Tianwen Yin, Huixian Xin, Jinming Yu, Feifei Teng · 2021 · Biomarker Research
90. PD-1 preferentially inhibits the activation of low-affinity T cells
    Kenji Shimizu, Daisuke Sugiura, Il‐mi Okazaki, Takumi Maruhashi, Tatsuya Takemoto, Taku Okazaki · 2021 · Proceedings of the National Academy of Sciences
91. Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
    Vasu R. Sah, Joakim W. Karlsson, Henrik Jespersen, Mattias F. Lindberg, Lisa M. Nilsson, Lars Ny, Jonas A. Nilsson · 2021 · Melanoma Research
92. Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
    Yu-meng Wang, Jun-jun Qiu, Xin-yu Qu, Jing Peng, Chong Lu, Meng Zhang, Ming-Xing Zhang, Xing-ling Qi, Bin Lv, Jing-Jing Guo et al. · 2022 · OncoImmunology
93. Development and function of natural TCR+ CD8αα+ intraepithelial lymphocytes
    Yuanyuan Gui, Hao Cheng, Jingyang Zhou, Hao Ying Xu, Jiajia Han, Dunfang Zhang · 2022 · Frontiers in Immunology
94. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma
    Zhen Han, Xiwei Wu, Hanjun Qin, Yate‐Ching Yuan, Daniel B. Schmolze, Chingyu Su, Jasmine M. Zain, Lilach Moyal, Emmilia Hodak, James F. Sanchez et al. · 2023 · JCI Insight
95. Costimulatory blockade molecules and B-cell–mediated immune response: current knowledge and perspectives
    Claire Leibler, Allan Thiolat, Rebecca A. Elsner, Khalil El Karoui, Chloé Samson, Philippe Grimbert · 2019 · Kidney International
96. Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance
    Tijana Martinov, Brian T. Fife · 2019 · Annals of the New York Academy of Sciences
97. Molecular-scale spatio-chemical control of the activating-inhibitory signal integration in NK cells
    Esti Toledo, Guillaume Le Saux, Avishay Edri, Long Li, Maor Rosenberg, Yossi Keidar, Viraj Bhingardive, Olga Radinsky, Uzi Hadad, Carmelo Di Primo et al. · 2021 · Science Advances
98. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Yuan, Yuan, Kos, Ferdynand J., He, Ting-Fang, Yin, Hongwei H., Li, Mengsha, Hardwick, Nicola, Zurcher, Kathryn, Schmolze, Daniel, Lee, Peter, Pillai, Raju K. et al. · 2017 · OncoImmunology
99. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
    Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi, Davod Tasa · 2022 · Biomedicine & Pharmacotherapy
100. Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges
     Sean H. Lim, Stephen A. Beers, Aymen Al‐Shamkhani, Mark Steven Cragg · 2023 · Clinical Cancer Research